About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
›
top-articles
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2.3
(top 20%)
impact factor
1.2K
(top 20%)
papers
18.4K
(top 10%)
citations
55
(top 10%)
h
-index
2.4
(top 20%)
extended IF
1.3K
all documents
20.3K
doc citations
85
(top 10%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2017
607
2
Screening for cognition and behaviour changes in ALS
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2014
421
3
A revision of the El Escorial criteria - 2015
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2015
373
4
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2014
293
5
Bulbar and speech motor assessment in ALS: Challenges and future directions
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2013
166
6
Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS)
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2014
157
7
Deciphering amyotrophic lateral sclerosis: What phenotype, neuropathology and genetics are telling us about pathogenesis
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2013
142
8
Premorbid body mass index and risk of amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2013
138
9
Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): A cognitive tool for motor disorders
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2015
138
10
Mechanisms, models and biomarkers in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2013
135
11
Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2020
133
12
Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2014
131
13
The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS)
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2016
125
14
Eye tracking communication devices in amyotrophic lateral sclerosis: Impact on disability and quality of life
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2013
123
15
Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2014
111
16
The Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen: A cross-sectional comparison of established screening tools in a German-Swiss population
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2015
109
17
Brain-computer interface (BCI) evaluation in people with amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2014
100
18
Involvement of spinal sensory pathway in ALS and specificity of cord atrophy to lower motor neuron degeneration
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2013
96
19
The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2013
88
20
Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2014
85
21
Emotional empathy in amyotrophic lateral sclerosis: a behavioural and voxel-based morphometry study
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2014
85
22
Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2016
84
23
Therapeutic effects of Cu
II
(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2013
82
24
Longitudinal structural changes in ALS: a three time-point imaging study of white and gray matter degeneration
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2018
82
25
Identification of RNA bound to the TDP-43 ribonucleoprotein complex in the adult mouse brain
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2013
77
26
Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2015
76
27
Neurofilaments in pre-symptomatic ALS and the impact of genotype
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2019
76
28
High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: A prospective interventional study
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2013
75
29
The involvement of the cerebellum in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2013
75
30
Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2015
75
31
Is exposure to cyanobacteria an environmental risk factor for amyotrophic lateral sclerosis and other neurodegenerative diseases?
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2013
72
32
Prognostic value of efficiently correcting nocturnal desaturations after one month of non-invasive ventilation in amyotrophic lateral sclerosis: A retrospective monocentre observational cohort study
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2013
71
33
The natural history of motor neuron disease: Assessing the impact of specialist care
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2013
70
34
The El Escorial criteria: Strengths and weaknesses
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2015
69
35
Primary lateral sclerosis: a distinct entity or part of the ALS spectrum?
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2019
69
36
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2013
68
37
Incorporation of telehealth into a multidisciplinary ALS Clinic: feasibility and acceptability
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2017
67
38
Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2020
66
39
Csf p-tau
181
/tau ratio as biomarker for TDP pathology in frontotemporal dementia
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2015
65
40
Mind the gap: The mismatch between clinical and imaging metrics in ALS
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2015
65
41
The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2016
65
42
Eye-tracking in amyotrophic lateral sclerosis: A longitudinal study of saccadic and cognitive tasks
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2016
65
43
Identifying behavioural changes in ALS: Validation of the Beaumont Behavioural Inventory (BBI)
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2017
64
44
pNfH is a promising biomarker for ALS
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2013
63
45
Attitudes towards hastened death in ALS: A prospective study of patients and family caregivers
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2014
63
46
Neuroimaging patterns along the ALS-FTD spectrum: a multiparametric imaging study
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2017
63
47
Screening for cognitive dysfunction in ALS: validation of the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) using age and education adjusted normative data
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2017
63
48
Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2017
63
49
Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2019
63
50
Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2014
62
site/software ©
exaly
; All materials licenced under
CC by-SA
.